The year 2025 has marked a pivotal era in oncology, with rapid advancements transforming how we detect, treat, and prevent cancer. Driven by innovations in immunotherapy, precision medicine, artificial intelligence (AI), and novel vaccines, researchers worldwide have accelerated progress against a disease that claims nearly 10 million lives every year. From early detection tools identifying stage I cancers with unprecedented accuracy to personalized mRNA therapies reducing recurrence risks, these breakthroughs promise more targeted, less toxic treatments. As global oncology spending surges toward 180 billion by 2028, the focus remains on equitable access and addressing disparities in low- and middle-income countries (LMICs), where 70% of cancer deaths occur. Immunotherapy continues to dominate 2025’s landscape, with chimeric antigen receptor (CAR) T-cell therapies expanding beyond blood cancers. Researchers have engineered “EchoBack CAR T-cells, ”1 which are activated by ultrasound to destroy tumors for up to five times longer than traditional versions. These cells target solid tumors, such as breast and brain cancers, with reduced fatigue and improved safety. This addresses key limitations in solid tumor penetration and persistence, potentially revolutionizing treatments for aggressive malignancies. The 2025 Nobel Prize in Medicine was awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi, who highlighted regulatory T-cells in immune tolerance, paving the way for therapies that prevent autoimmune reactions while boosting anticancer responses. Antibody-drug conjugates (ADCs) and bispecific antibodies also advanced, with novel targets for previously “undruggable” proteins like KRAS. In lung cancer, trials of tarlatamab outperformed chemotherapy in recurrent small cell carcinoma cases, reducing symptoms like cough. 2 These strides underscore immunotherapy’s shift toward combination strategies, including checkpoint inhibitors and cellular therapies, potentially curing more patients. Precision oncology, projected to grow at 8% through 2030, leverages genomics and biomarkers for customized care. In breast cancer, the DESTINY-Breast09 trial results positioned ADCs like trastuzumab deruxtecan as first-line for HER2-positive metastatic cases, 3 improving outcomes over prior standards. For ovarian cancer, a new approach targeting mitogen-activated protein kinase (MAPK) pathway hyperactivity, common despite genetic diversity, combined with drugs to inhibit growth and resistance. In prostate cancer, AI models identified high-risk patients for androgen receptor inhibitors, optimizing abiraterone use. These efforts address underfunded cancers such as pancreatic and brain, with gene therapies potentially curing sickle cell-related complications. AI’s integration has revolutionized diagnostics, with tools like City of Hope’s (HopeLLM) summarizing histories and matching trials. Stanford’s multimodal transformer with Unified maSKed (MUSK) model combines images and text to predict prognoses and immunotherapy responses across cancers, outperforming traditional methods. Harvard’s ChatGPT-like AI performs multi-cancer diagnostics, identifying nonresponders to therapies. Early detection tests shone brightly: An assay identified 18 stage I cancers with 93% accuracy in men. University of California, San Diego’s extracellular vesicle biomarkers detected 95% of early pancreatic cancers. AI-driven spatial transcriptomics advanced the understanding of tumor progression. Health and human services of the United States (HHS) doubled funding for AI-backed pediatric cancer research via the Childhood Cancer Data Initiative. The mRNA-4157 plus pembrolizumab cut melanoma recurrence by 44%. 4 Experts predict the first commercial mRNA vaccine by 2029, with accelerated Food and Drug Administration (FDA) approvals. The Cancer Vaccine Launch Pad trials personalized vaccines across Europe, using mRNA for up to 15 doses. There is a buzz going around about Russia’s genetic-data-targeted vaccine rollout, which highlights global momentum. Despite progress, hurdles persist: Immunotherapy resistance, solid tumor barriers, and access inequities in LMICs. 2025’s innovations resulted in over 20 FDA of the USA approvals, including first-in-class therapies, which signal a shift to multimodal, patient-centric care. With AI, vaccines, and precision tools, the horizon brightens for cures. As experts forecast, addressing disparities and novel targets like molecular glues will define oncology’s next decade.
Manigreeva Krishnatreya (Tue,) studied this question.